Alan M. Seddon

London, ENG KT12EE, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 22 publications

Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.

Advancements in Targeted Therapies for Colorectal Cancer: Overcoming Challenges and Exploring Future Directions.

Journal: Cancers

Published: July 14, 2025

Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.

Expression of EGFRvIII and its co‑expression with wild‑type EGFR, or putative cancer stem cell biomarkers CD44 or EpCAM are associated with poorer prognosis in patients with hepatocellular carcinoma.

Journal: Oncology reports

Published: April 29, 2024

The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells.

The Combination of Afatinib With Dasatinib or Miransertib Results in Synergistic Growth Inhibition of Stomach Cancer Cells.

Journal: World journal of oncology

Published: November 18, 2023

Detection of high-risk Human Papillomavirus in prostate cancer from a UK based population.

Detection of high-risk Human Papillomavirus in prostate cancer from a UK based population.

Journal: Scientific reports

Published: June 30, 2022

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer.

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer.

Journal: Cancers

Published: January 07, 2021

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer.

Journal: Oncology reports

Published: July 15, 2020

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer.

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer.

Journal: Oncotarget

Published: January 15, 2019

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.

Co-expression and prognostic significance of the HER family members, EGFRvIII, c-MET, CD44 in patients with ovarian cancer.

Journal: Oncotarget

Published: November 03, 2017

CmeABC Multidrug Efflux Pump Contributes to Antibiotic Resistance and Promotes Campylobacter jejuni Survival and Multiplication in Acanthamoeba polyphaga.

CmeABC Multidrug Efflux Pump Contributes to Antibiotic Resistance and Promotes Campylobacter jejuni Survival and Multiplication in Acanthamoeba polyphaga.

Journal: Applied and environmental microbiology

Published: July 21, 2017

YPTB3816 of Yersinia pseudotuberculosis strain IP32953 is a virulence-related metallo-oligopeptidase.

YPTB3816 of Yersinia pseudotuberculosis strain IP32953 is a virulence-related metallo-oligopeptidase.

Journal: BMC microbiology

Published: September 03, 2016

Potential probiotic-associated traits revealed from completed high quality genome sequence of Lactobacillus fermentum 3872.

Potential probiotic-associated traits revealed from completed high quality genome sequence of Lactobacillus fermentum 3872.

Journal: Standards in genomic sciences

Published: August 23, 2016

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines.

Journal: Scientific reports

Published: August 17, 2016

Showing 1-12 of 22

Last Updated: 09/26/2026